1.
Arbelo E,ProtonotariosA<span dir="RTL">,</span>Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. <em>Eur Heart J</em>. 2023;(44):3503-3626
2.
McDonagh TA,Metra M,Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <em>Eur Heart J.</em> 2021;(42):3599-3726.
3.
HeidenreichPA,Bozkurt B,AguilarD, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. <em>Circulation.</em> 2022;(145):895-1032.
4.
Elliott P. Diagnosis and management of dilated cardiomyopathy. <em>Heart.</em> 2000;(84):106-112.
5.
Regitz-Zagrosek V,Roos-Hesselink JW,Bauersachs J, et al. ESC Guidelines for the management of cardiovascular diseases during pregnancy. <em>Eur Heart J</em>. 2018;(39):3165-3241.
6.
Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the heart failure association of the european society of cardiology study group on peripartum cardiomyopathy. <em>Eur J Heart Fail</em>. 2019;(21):827-843.
7.
Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. <em>J Am Coll Cardiol</em>. 2020;(75):207-221.
8.
Van Spaendonck-Zwarts KY, Van Tintelen JP, Van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. <em>Circulation</em>. 2010;(121):2169-2175.
9.
Zhang X,SunY,Zhang Y, et al. Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction. <em>ESC Heart Fail</em>. 2021;(8):5383-5391.
10.
Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. <em>Behav Res Methods.</em> 2009;(41):1149-1160.
11.
Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart failure with recovered left ventricular ejection fraction: jacc scientific expert panel. <em>J Am Coll Cardiol.</em> 2020;(76):719-734.
12.
Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography. <em>J Am Soc Echocardiogr</em>. 2019;(32):1-64.
13.
Karaye KM, Ishaq NA, Sa’idu H, et al. Incidence, clinical characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from the PEACE Registry. <em>ESC Heart Fail.</em> 2020;(7):235-243.
14.
Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. <em>Circ J</em>. 2011;(75):1975-1981.
15.
Sliwa K, Petrie MC, van der Meer P, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <em>Eur Heart J.</em> 2020;(41):3787-3797.
16.
Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. <em>Int J Cardiol</em>. 2002;(86):311-316.
17.
Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. <em>Clin Rev Allergy Immunol</em>. 2002;(23):301-324.
18.
van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. <em>Eur Heart J</em>. 2014;(35):2165-2173.
19.
Lamparter S, Pankuweit S, Maisch B. Clinical and immunologic characteristics in peripartum cardiomyopathy. <em>Int J Cardiol</em>. 2007;118(1):14-20. doi:10.1016/j.ijcard.2006.04.09018.
20.
Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. <em>N Engl J Med</em>. 2016; 374(3):233-241.
21.
McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study. <em>J Am Coll Cardiol</em>. 2015;(66):905-914.
22.
Punnoose LR, Givertz MM, Lewis EF, et al. Heart failure with recovered ejection fraction: a distinct clinical entity. <em>J Card Fail. </em>2011;(17):527-532.
23.
Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. <em>JAMA Cardiol</em>. 2016;(1):510-518.
24.
Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. <em>Circulation.</em>2014;(129):2380-2387.
25.
Ruwald MH, Solomon SD, Foster E, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT) trial. <em>Circulation.</em> 2014;(130):2278-2286
26.
Cho JY,Kim KH,Song JE, et al. Predictors of left ventricular functional recovery and their impact on clinical outcomes in patients with newly diagnosed dilated cardiomyopathy and heart failure. <em>Heart Lung Circ.</em> 2018;(27):41-49.
27.
Matsumura Y, Hoshikawa-Nagai E, Kubo T, et al. Left ventricularreversere modeling in long-term (>12years) survivors withidiopathic dilated cardiomyopathy. Am J Cardiol. 2013;(111):106-110.
28.
Wilcox JE, Fonarow GC, Yancy CW, et al. Factors associatedwith improvement in ejection fraction in clinical practice amongpatients with heart failure: findings from improve HF. Am HeartJ. 2012;(163):49-56.
29.
Aimo A, Vergaro G, Castiglione V, et al. Effect of sex on reverseremodeling in chronic systolic heart failure. JACC Heart Fail.2017;(5):735-742.
30.
Sze E, Samad Z, Dunning A, et al. Impaired recovery of leftventricular function in patients with cardiomyopathy and leftbundle branch block. J Am Coll Cardiol. 2018;(71):306-317.
31.
Carpenito M, Fanti D, Mega S, et al. The central role of left atriumin heart failure. Front Cardiovasc Med. 2021;(8):704-762.
32.
Zhu N, Che H, Zhao X, et al. Left atrial diameter in heart failurewith left ventricular preserved, mid-range, and reduced ejectionfraction. Medicine. 2019;(98):18146.
33.
Carluccio E, Dini FL, Biagioli P, et al. The ‘Echo Heart FailureScore’: an echocardiographic risk prediction score of mortality insystolic heart failure. Eur J Heart Fail. 2013;(15):868-876.
34.
Bosch L, Carluccio E, Coiro S, et al. Risk stratification of asianpatients with heart failure and reduced ejection fraction: theeffectiveness of the echo heart failure score: risk stratificationof asian patients with heart failure and reduced ejectionfraction. Eur J Heart Fail. 2017;(19):1732-1735.
35.
Rocha BML, Cunha GJL, Falcao Menezes LF. The burden ofiron deficiency in heart failure: therapeutic approach. J Am CollCardiol. 2018;(71):782-793.
36.
Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferricderisomaltose in patients with heart failure and iron deficiencyin the UK (IRONMAN): an investigator-initiated, prospective,randomised, open-label, blinded-endpoint trial. Lancet. 2022;(400):2199-2209.
37.
Ponikowski P, Kirwan BA, Anker SD, , et al. Ferric carboxymaltosefor iron deficiency at discharge after acute heart failure: amulticentre, double-blind, randomised, controlled trial. Lancet.2020;(396):1895-1904.
38.
Salah HM, Savarese G, Rosano GMC, et al. Intravenous ironinfusion in patients with heart failure: a systematic review andstudy-level meta-analysis. ESC Heart Fail. 2023;(10):1473-1480.